NuCana (NCNA) Income from Continuing Operations (2017 - 2025)
NuCana's (NCNA) quarterly Income from Continuing Operations came in at 3494346.6 in Q4 2025, down 244.62% year-on-year from 2416200.99 in Q4 2024, and down 313.68% quarter-over-quarter from 844700.7 in Q3 2025.
NuCana (NCNA) Income from Continuing Operations (2017 - 2025) Analysis & Trends
NuCana has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 3494346.6 for Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 3494346.6, down 244.62% year-over-year; the trailing twelve-month figure through Dec 2025 was 40505140.46 (down 41.62% YoY), and the FY2025 annual result was 38702233.89, down 59.38% from the prior year.
- Income from Continuing Operations came in at 3494346.6 for Q4 2025 at NuCana, down from 844700.7 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 844700.7 in Q3 2025 to a low of 32606744.62 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 10382161.24 (2024), against an average of 11093411.51.
- Across the five-year window, Income from Continuing Operations surged 90.89% in 2024 and sank 244.62% in 2025, its largest moves.
- NuCana's Income from Continuing Operations stood at 21183986.69 in 2021, then climbed by 6.1% to 19891691.4 in 2022, then surged by 44.03% to 11133132.41 in 2023, then soared by 90.89% to 1013966.45 in 2024, then tumbled by 244.62% to 3494346.6 in 2025.
- The last three Income from Continuing Operations figures came in at 3494346.6 (Q4 2025), 844700.7 (Q3 2025), and 32606744.62 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | -3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.49 Mn |
| Sep 30, 2025 | -844,700.70 |
| Jun 30, 2025 | -32.61 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | -6.82 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -10.33 Mn |
| Dec 31, 2023 | -11.13 Mn |
| Sep 30, 2023 | -10.26 Mn |
| Jun 30, 2023 | -7.63 Mn |
| Mar 31, 2023 | -10.77 Mn |
| Dec 31, 2022 | -19.89 Mn |
| Sep 30, 2022 | -7.04 Mn |
| Jun 30, 2022 | -6.40 Mn |
| Mar 31, 2022 | -14.00 Mn |
| Dec 31, 2021 | -21.18 Mn |
| Sep 30, 2021 | -13.72 Mn |
| Jun 30, 2021 | -14.92 Mn |
| Mar 31, 2021 | -15.81 Mn |